Time New York: Thu 18 Jan 13:05 pm  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

Can Centennial Resource (CDEV) Run Higher on Strong Earnings Estimate Revisions?

Zacks

Centennial Resource Development, Inc. CDEV operates as an independent oil and natural gas company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on CDEV’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Centennial Resource could be a solid choice for investors.

Current Quarter Estimates for CDEV

In the past 30 days, one estimate has gone higher for Centennial Resource while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 9 cents a share 30 days ago, to 10 cents today, a move of 11.1%.

Current Year Estimates for CDEV

Meanwhile, Centennial Resource current year figures are also looking quite promising, with two estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from 25 cents per share 30 days ago to 27 cents per share today, an increase of 8%.

CENTENNIAL RES Price and Consensus

CENTENNIAL RES Price and Consensus | CENTENNIAL RES Quote


Bottom Line

The stock has also started to move higher lately, adding 6.6% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.